PT  - JOURNAL ARTICLE
AU  - HIRANO, AKIRA
AU  - SHIMIZU, TADAO
AU  - IMAMURA, HIROSHI
AU  - WATANABE, OSAMU
AU  - KINOSHITA, JUN
AU  - OKABE, TOSHIHIRO
AU  - KIMURA, KIYOMI
AU  - KAMIMURA, MARI
AU  - DOMOTO, KAORU
AU  - AIBA, MOTOHIKO
AU  - OGAWA, KENJI
TI  - The Combination of Epirubicin plus Docetaxel as Neoadjuvant Chemotherapy in Locally-advanced Breast Cancer
DP  - 2006 Jan 01
TA  - Anticancer Research
PG  - 581--584
VI  - 26
IP  - 1B
4099  - http://ar.iiarjournals.org/content/26/1B/581.short
4100  - http://ar.iiarjournals.org/content/26/1B/581.full
SO  - Anticancer Res2006 Jan 01; 26
AB  - Background: The purpose of this study was to evaluate the activity and toxicity of epirubicin plus docetaxel as neoadjuvant chemotherapy for locally advanced breast cancer. Patients and Methods: In this single-center, phase II trial, twenty-one patients with locally advanced breast cancer (T>3 cm or N>1) received epirubicin (70 mg/m2) and docetaxel (60 mg/m2) on Day 1 of each cycle for up to 6 cycles. Results: Clinically complete responses (CR) were observed in 5 patients and partial responses were observed in 14 patients. The clinical response rate was 90.5% (95% confidence interval, 78.0-99.9). Eleven patients (52.4%) underwent breast conserving surgery. Pathological response evaluation revealed 2 CR (9.5%). Grade 4 neutropenia was recorded in 81.0% of the patients and febrile neutropenia occurred in 1 patient. Conclusion: The combination of epirubicin plus docetaxel was an active and well-tolerated treatment for locally-advanced breast cancer. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved